Digestive Health Recognition Program (DHRP)

The AGA Digestive Health Recogniton Program: Demonstrate Quality, Achieve Recognition, Qualify for Incentives and Avoid Penalties

The AGA Digestive Health Recognition Program™ (DHRP) is a quality improvement program and clinical data registry that allows clinicians to demonstrate quality of care in the management of patients with hepatitis C virus (HCV) and/or inflammatory bowel disease (IBD). The DHRP also offers a Qualified Clinical Data Registry (QCDR) that covers multiple clinical topics. Each of the three DHRP modules allow participants to submit data for the CMS Physician Quality Reporting System (PQRS).

Program made possible by support from: AbbVie; Gilead Science, Inc.; Janssen Biotech, Inc. and Janssen Therapeutics, Division of Janssen Products, LLP.; Shire Pharmaceuticals.

Benefits

DHRP provides clinicians with a fast, simple way to:

  • Monitor your performance on quality measures.
  • Benchmark yourself in relation to your peers.
  • Avoid significant Medicare reimbursement penalties by qualifying for PQRS.
  • Identify gaps in care and improve patient outcomes.
  • Report on as few as 20 patients.
  • Take advantage of a low-cost program for a high-value return.
 

REGISTER Today

All GIs are eligible to participate in one or more of the three DHRP modules.

Registration and data entry for all three 2016 DHRP modules is now open.

Register for the 2016 AGA QCDR:

Register

Register for the 2016 HCV or IBD modules:

Register

Already participating in DHRP?

Sign into the Medconcert platform

Sign in
 

Pricing

AGA members pay only $300 per disease state. Non-AGA members are welcome to participate for a fee of $550 per disease state.

Technical Requirements

Please note: the DHRP platform works best using Google Chrome or Mozilla Firefox.

 

For pre-registration questions or technical support, please email support@medconcert.com or call 888-669-7444. For additional information about the DHRP, please email recognition@gastro.org. For additional information about AGA's measures, please email measures@gastro.org.

Measures

AGA has been at the forefront of performance measures work since 2006. AGA has developed measures around several digestive health conditions and clinical topics. AGA serves as measure steward for many of the measures included in the three DHRP modules.

 

HCV Quality Measures

2016 DHRP HCV Measures

 
Hepatitis C: HCV Ribonucleic Acid (RNA) Testing Before Initiating Treatment (PQRS #84 / NQF 0395) *
Hepatitis C: HCV Genotype Testing Prior to Treatment (PQRS #85 / NQF 0396) *
Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4–12 Weeks After Initiating Treatment (PQRS #87 / NQF 0398) *
Documentation of Current Medications in the Medical Record (PQRS #130 / NQF 0419) *
Hepatitis C: Hepatitis A Vaccination (PQRS #183 / NQF 0399) *
Hepatitis B Vaccination in Patients with HCV (non-PQRS Measure / NQF n/a)
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention (PQRS #226 / NQF 0028) *
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options (PQRS #390 / NQF n/a) *
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Hepatitis C Cirrhosis (PQRS #401 / NQF n/a) *
Hepatitis C Virus (HCV): Sustained Virological Response (non-PQRS measure / NQF n/a)
* 2016 PQRS HCV Measures Group

IBD Quality Measures

2016 DHRP IBD Measures

Preventive Care and Screening: Influenza Immunization (PQRS #110 / NQF 0041) *
Pneumonia Vaccination Status for Older Adults (PQRS #111 / NQF 0043) *
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention (PQRS #226 / NQF 0028) *
IBD Type, Anatomic Location and Activity (non-PQRS Measure)
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy (PQRS #270 / NQF n/a) *
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury — Bone Loss Assessment (PQRS #271 / NQF n/a) *
Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy (PQRS #274 / NQF n./a) *
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy (PQRS #275 / NQF n/a) *
* 2016 PQRS IBD Measures Group
 

QCDR Quality Measures

2016 DHRP QCDR MEASURES

Colonoscopy Interval for Patients with a History of Adenomatous Polyps — Avoidance of Inappropriate Use (PQRS #185 / NQF 0659)
Appropriate Follow-­Up Interval for Normal Colonoscopy in Average Risk Patients (PQRS #320 / NQF 0658)
Screening Colonoscopy Adenoma Detection Rate (PQRS #343 / NQF n/a)
Photodocumentation of Cecal Intubation (PQRS #425 / NQF n/a)
Age Appropriate Screening Colonoscopy (PQRS #439 / NQF n/a)
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options (PQRS #390 / NQF n/a)
One-Time Screening for Hepatitis C (HCV) for Patients at Risk (PQRS #400 / NQF n/a)
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis (PQRS #401 / NQF n/a)
Hepatitis C Virus (HCV): Sustained Virological Response (non-PQRS measure / NQF n/a)
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy (PQRS #270 / NQF n/a)
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment (PQRS #271 / NQF n/a)
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy (PQRS #275 / NQF n/a)
Preventive Care and Screening: Influenza Immunization (PQRS #110 / NQF 0041)
Pneumonia Vaccination Status for Older Adults (PQRS #111 / NQF 0043)
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-­Up Plan (PQRS #128 / NQF 0421)
Documentation of Current Medications in the Medical Record (PQRS #130 / NQF 0419)
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention (PQRS #226 / NQF 0028)
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented (PQRS #317 / NQF n/a)
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling (PQRS #431 / NQF n/a)

PQRS

CMS will level a -2.0 percent payment adjustment in 2018 if practices do not report PQRS data on quality measures for covered professional services furnished to Medicare beneficiaries in 2016. Reporting on quality measures for PQRS is accomplished through two different reporting options:

  • Participants in the HCV and IBD modules can report to PQRS though the qualified registry reporting option. This option requires reporting on 20 patients, a majority of whom must be Medicare Part B fee-for-service patients.

  • Participants in the AGA QCDR can report to PQRS through the qualified clinical data registry reporting option. For 2016, this option requires reporting on nine quality measures across three National Quality Strategy domains, including 2 outcome measures (or 1 outcome measure and 1 measure of the following measure type - resource use, patient experience of care, efficiency/appropriate use or patient safety), for 50 percent of a participant’s patients seen in 2016.

 

 

BROUGHT TO YOU AS PART OF THE
AGA Roadmap to the Future of GI